Heparanase: a universal immunotherapeutic target in human cancers.
Heparanase: a universal immunotherapeutic target in human cancers.
复制标题
DOI：
10.1016/j.drudis.2011.02.015
复制
发表时间：
2011-05
影响因子：
7.4
通讯作者：
Yafei Zhang;Xu-dong Tang;Jin-hua Gao;D. Fang;Shi-ming Yang
中科院分区：
文献类型：
--
作者：
Yafei Zhang;Xu-dong Tang;Jin-hua Gao;D. Fang;Shi-ming Yang
乙酰肝素酶已被确定为在转移中特别重要的参与者，并且其表达与各种肿瘤的转移扩散直接相关。免疫治疗的理想靶点是在正常组织中沉默但在癌症中过表达的基因产物，并且直接参与肿瘤细胞的生存和进展。转移是肿瘤进展的顶点。乙酰肝素酶在转移中的重要作用意味着通过下调乙酰肝素酶表达的免疫逃逸可以降低癌症的死亡率。乙酰肝素酶的这些特性使其成为肿瘤免疫治疗的一个有吸引力的通用靶标。在这里，我们回顾了目前的知识，乙酰肝素酶及其参与肿瘤转移，重点是最近的结果，乙酰肝素酶为靶向的癌症免疫治疗研究。
Heparanase has been identified as a particularly important player in metastasis, and its expression directly correlates with the metastatic spread of various tumors. Ideal targets for immunotherapy are gene products that are silenced in normal tissues but overexpressed in cancer, and that are directly involved in tumor cell survival and progression. Metastasis is the culmination of neoplastic progression. The importance of the role of heparanase in metastasis implies that immune escape by downregulation of heparanase expression could reduce the mortality of the cancer. These characteristics of heparanase make it an attractive universal target for cancer immunotherapy. Here, we review current knowledge about heparanase and its involvement in tumor metastasis, with an emphasis on recent results from heparanase-targeted cancer immunotherapy studies.